Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke

Treatment of Homonymous Visual Loss With Digital Therapeutics, VIVID Brain, Visual Perceptual Learning Device (HOGWAND Trial) : Multi Center, Randomized, Single-blind (Evaluator), Superiority Prove, Prospective Confirmatory Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05525949

Enrollment

Registered

2022-09-02

Start date

2022-10-19

Completion date

2023-11-08

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visual Fields Hemianopsia, Hemianopsia, Homonymous

Keywords

Visual field defect, Visual perceptual learning, Humphrey visual field

Brief summary

This study evaluates the efficacy of visual perceptual learning for the treatment of visual field defect caused by brain disease. Half of participants will receive visual perceptual training using the VIVID Brain. The other half will not receive any training because there is no standard treatment for visual field defect caused by brain disease.

Interventions

DEVICEVIVID Brain

Participants receive visual perceptual training using the VIVID Brain software.

OTHERNo-treatment Control

No-treatment is administered during control period.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* 19 years and older * At least 3 months after brain disease related to visual field defect * Verified brain disease in visual pathway related to occipital lobe, parietal lobe, temporal lobe or etc. using CT or MRI * Brain disease induced visual field defect * Able to use the VR(Virtual Reality) device * Able to use the app with a smart phone * Patient/legally authorized representative has signed the informed consent form

Exclusion criteria

* Complete hemianopsia * Epilepsy, photosensitivity, Parkinson's disease * Bilateral visual field defect * Hemispatial neglect * Ophthalmologic disorder that may interfere the trial. (Ptosis of Eyelid, Corneal Opacity, Diabetic Retinopathy, Glaucoma, Macular Degeneration etc.) * Inability to discontinue psychostimulants such as methylphenidate, modafinil, and amphetamine. * Candidate for carotid endarterectomy or stenting * Received ophthalmologic surgery or laser surgery within 3 months, except for the cataract surgery * Pregnant or breast feeding * Participating in other clinical trial * Any other condition that, in the opinion of the investigator, precludes participation in the trial

Design outcomes

Primary

Measure	Time frame	Description
The sum of improved areas compared to baseline in the whole field	12 weeks	The sum of areas where sensitivity increased by more than 6 dB compared to baseline in the whole field measured by Humphrey visual field test. The improved area ranges between 0 and 2,736 degree\^2, of which larger area indicates better outcome.

Secondary

Measure	Time frame	Description
The sum of improved areas compared to baseline in the affected hemi-field	12 weeks	The sum of areas where sensitivity increased by more than 6 dB compared to baseline in the affected hemi-field measured by Humphrey visual field test.
Changes in perimetric mean deviation relative to baseline in the whole field	12 weeks	Changes in perimetric mean deviation relative to baseline in the whole field measured by Humphrey visual field test.
Changes in mean total deviation relative to baseline in the affected hemi-field	12 weeks	Changes in mean total deviation relative to baseline in the affected hemi-field measured by Humphrey visual field test.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026